

Product Monograph
Including Patient Medication Information

Pr TRIFLUOPERAZINE

Trifluoperazine Tablets

For Oral use

1 mg, 2 mg, 5 mg, 10 mg and 20 mg of trifluoperazine (as trifluoperazine hydrochloride)

BP

Antianxiety-Antiemetic-Antipsychotic

AA PHARMA INC.
1165 Creditstone Road, Unit #1
Vaughan, Ontario
L4K 4N7
www.aapharma.ca/en/

Date of Authorization:
April 16, 2025

Control Number: 291671

Recent Major Label Changes

7 Warnings and Precautions, Ophthalmologic	2025-04
7 Warnings and Precautions, 7.1.2 Breastfeeding	2025-04

Table of Content

Certain sections or subsections that are not applicable at the time of the preparation of the most recent authorized product monograph are not listed.

Recent Major Label Changes	2
Table of Content	2
Part 1: Healthcare Professional Information	4
1 Indications.....	4
1.1 Pediatrics	4
1.2 Geriatrics	4
2 Contraindications.....	4
3 Serious Warnings and Precautions Box.....	5
4 Dosage and Administration	5
4.1 Dosing Considerations.....	5
4.2 Recommended Dose and Dosage Adjustment	5
4.4 Administration.....	6
4.5 Missed Dose	6
5 Overdose	6
6 Dosage Forms, Strengths, Composition, and Packaging.....	7
7 Warnings and Precautions	8
General	8
Carcinogenesis and Mutagenesis.....	8
Cardiovascular	9
Dependence, Tolerance, and/or Abuse Liability	10
Driving and Operating Machinery	10
Endocrine and Metabolism	10
Gastrointestinal	10
Genitourinary	11

	Hematologic	11
	Hepatic/Biliary/Pancreatic	11
	Monitoring and Laboratory Tests.....	11
	Neurologic	11
	Ophthalmologic.....	12
	Skin.....	12
	7.1 Special Populations	12
	7.1.1 Pregnancy.....	12
	7.1.2 Breastfeeding	13
	7.1.3 Pediatrics	13
	7.1.4 Geriatrics	13
8	Adverse Reactions	14
	8.1 Adverse Reaction Overview	14
9	Drug Interactions.....	17
	9.1 Serious Drug Interactions.....	17
	9.2 Drug Interactions Overview	17
	9.3 Drug-Behaviour Interactions.....	18
	9.4 Drug-Drug Interaction	18
	9.5 Drug-Food Interactions	21
	9.6 Drug-Herb Interactions	22
	9.7 Drug-Laboratory Test Interactions.....	22
10	Clinical Pharmacology.....	22
	10.1 Mechanism of Action	22
	10.2 Pharmacodynamics	23
	10.3 Pharmacokinetics	23
11	Storage Stability, and Disposal.....	23
	Part 2: Scientific Information	24
13	Pharmaceutical Information	24
14	Clinical Trials	24
16	Non-Clinical Toxicology.....	24
	Patient Medication Information.....	25

Part 1: Healthcare Professional Information

1 Indications

TRIFLUOPERAZINE (trifluoperazine tablets) is indicated for:

- Control of excessive anxiety, tension and agitation seen in neuroses or associated with somatic conditions.
- Treatment or prevention of nausea and vomiting of various causes.
- Management of psychotic disorders, such as acute or chronic catatonic, hebephrenic and paranoid schizophrenia; psychosis due to organic brain damage, toxic psychosis, and the manic phase of manic-depressive illness.

1.1 Pediatrics

Pediatrics (<6 years of age): The safety and efficacy of trifluoperazine tablets in children under the age of 6 years have not been studied; therefore, Health Canada has not authorized an indication for children under the age of 6 years. See [7.1.3 Pediatrics](#).

1.2 Geriatrics

Geriatrics (≥65 years of age): TRIFLUOPERAZINE is not indicated in elderly patients with dementia. The safety and efficacy of trifluoperazine tablets in patients 65 years of age or older have not been studied. See [3 Serious Warnings and Precautions Box](#) and [7.1.4 Geriatrics](#).

2 Contraindications

TRIFLUOPERAZINE is contraindicated in:

- Patients who are hypersensitive to this drug, to phenothiazines or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing. See [6 Dosage Forms, Strengths, Composition, and Packaging](#).
- Comatose or greatly depressed states due to CNS depressants.
- Blood dyscrasias and bone marrow depression.
- Liver damage.
- Patients with congenital long QT syndrome or with a family history of this syndrome and in patients with a history of cardiac arrhythmias or Torsade de Pointes. A pre-treatment ECG is thus recommended to exclude these conditions. TRIFLUOPERAZINE should not be used in the case of acquired long QT interval, such as associated with concomitant use of drugs known to prolong the QT interval (see [9.2 Drug Interactions Overview, Drugs that Prolong QT Interval](#)), known hypokalemia or hypomagnesemia, or clinically significant bradycardia.
- Combination with serotonin reuptake inhibitors, such as citalopram. See [9.2 Drug Interactions Overview, SSRI \(Selective Serotonin Reuptake Inhibitor\) Antidepressants](#).

3 Serious Warnings and Precautions Box

Serious Warnings and Precautions

- **Increased Mortality in Elderly Patients with Dementia:** Elderly patients with dementia treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo (See [7.1.4 Geriatrics, Use in Geriatric Patients with Dementia](#)). TRIFLUOPERAZINE is not approved for use in elderly patients with dementia.

4 Dosage and Administration

4.1 Dosing Considerations

- TRIFLUOPERAZINE dosage must be adjusted to the severity of the symptoms under treatment, and to the response of the individual. Particularly in psychiatric patients, dosage should be titrated carefully in order to achieve maximum therapeutic effect with the lowest possible dose, thereby minimizing the occurrence of unwanted side effects.
- **Debilitated patients:** Debilitated patients usually require a lower initial dose and more gradual dosage titration than do younger and healthier patients.
- **Geriatrics:** Geriatrics usually require a lower initial dose and more gradual dosage titration than do younger and healthier patients.
- **Liver disease:** Trifluoperazine is metabolized in the liver, dose reductions should be considered in patients with hepatic dysfunction.
- **Long-term therapy:** Prolonged administration of trifluoperazine at high dosages carries the risk of cumulative effects, with sudden onset of severe CNS or vasomotor symptoms. Periodic evaluations are recommended to assess continued dosage (see [7 Warnings and Precautions, General, Long-term therapy](#)).

4.2 Recommended Dose and Dosage Adjustment

Adults:

Mild to moderate symptoms: Usual dosage is 1 or 2 mg twice daily. If necessary, dosage may be increased to 6 mg daily but above this level extrapyramidal symptoms are more likely to occur in some patients.

Moderate to severe symptoms: The usual starting dose is 5 mg administered orally 2 or 3 times daily. Dosage should be increased gradually. The majority of patients will show optimum response on 15 to 20 mg/day, although a few may require 40 mg or more. Some patients have been given 80 mg or more daily, but there is now every evidence that such high dosages are rarely necessary. Optimum dosage levels are usually reached within 2 or 3 weeks after the start of therapy. It is important to maintain therapeutic dosage levels for a sufficient time to produce maximum

improvement. In most hospitalized acute cases, 2 to 3 weeks at optimum dosage will suffice before gradual reduction to maintenance dosage levels is begun.

Children: (6 to 12 years of age)

Behavior Disorders in Children: The usual dose is a 1 mg administered once or twice a day, depending on the child's bodyweight (see also below: [Psychotic children](#)).

Psychotic Children (either hospitalized or under adequate supervision.): The usual starting dose is a 1 mg administered once or twice daily, depending on the child's bodyweight. Dosage may be gradually increased until symptoms are controlled or until side effects become troublesome. Both the rate and the amount of dosage increases should be carefully adjusted to the weight and the severity of the symptoms, and the lowest effective dosage should always be used. Once control is achieved, it is usually possible to reduce dosage to a satisfactory maintenance level. In most cases, it is not necessary to exceed 15 mg of TRIFLUOPERAZINE daily.

4.4 Administration

Tablets are for oral administration.

4.5 Missed Dose

If a patient misses a dose, advise the patient to take the dose as soon as possible and continue with their regular schedule. If it is almost time for the next dose, advise the patient to skip the missed dose and continue with the next scheduled dose. Advise patients not to take 2 doses of TRIFLUOPERAZINE at the same time to make up for a missed dose.

5 Overdose

Symptoms: Signs and symptoms will be predominantly extrapyramidal. Lesser degrees of overdose may cause muscular twitching, drowsiness or dizziness. Symptoms of gross overdose may include CNS depression, weakness, tremor, torticollis and dystonia. Agitation and restlessness may occur. Salivation, dysphagia, or disturbances of gait may also be present.

Treatment: Essentially symptomatic and supportive. Gastric lavage is helpful if performed early. Do not attempt to induce emesis because a dystonic reaction of the head or neck may develop that could result in aspiration of vomitus.

The patient should be kept under careful observation and particular attention should be directed to maintaining an open airway, since involvement of the extrapyramidal mechanism may produce dysphagia and respiratory difficulty in severe cases of overdose.

If hypotension occurs, the standard measures for managing circulatory shock should be initiated. If it is desirable to administer a vasoconstrictor, norepinephrine or phenylephrine is most suitable.

Other pressor agents, including epinephrine, are not recommended because phenothiazine derivatives may reverse the usual elevating action of these agents and cause a further lowering of blood pressure.

Extrapyramidal symptoms may be treated with antiparkinsonism drugs (except levodopa) or diphenhydramine.

Limited experience indicates that phenothiazines are not dialyzable.

For the most recent information in the management of a suspected drug overdose, contact your regional poison control centre or Health Canada's toll-free number, 1-844 POISON-X (1-844-764-7669).

6 Dosage Forms, Strengths, Composition, and Packaging

Table 1 – Dosage Forms, Strengths, and Composition

Route of Administration	Dosage Form / Strength/Composition	Non-medicinal Ingredients
Oral	Tablet 1 mg, 2mg, 5mg, 10 mg and 20 mg of trifluoperazine (as trifluoperazine hydrochloride).	Carnauba wax, corn starch (1mg, 2mg), croscarmellose sodium (5mg, 10 mg and 20 mg), hydroxypropyl methylcellulose, lactose monohydrate, indigotine AL lake 12-14% (Blue #2), magnesium stearate, microcrystalline cellulose, polyethylene glycol and titanium dioxide.

TRIFLUOPERAZINE 1 mg: Each deep blue, round, biconvex, film-coated tablet, engraved 1 on one side contains trifluoperazine hydrochloride equivalent to 1 mg trifluoperazine. Available in bottles of 100 and 1000, and in unit dose packages of 100 (10 X10) tablets.

TRIFLUOPERAZINE 2 mg: Each deep blue, round, biconvex, film-coated tablet, engraved 2 on one side contains trifluoperazine hydrochloride equivalent to 2 mg trifluoperazine. Available in bottles of 100 and 1000, and in unit dose packages of 100 (10 X10) tablets.

TRIFLUOPERAZINE 5 mg: Each deep blue, round, biconvex, film-coated tablet, engraved 5 on one side contains trifluoperazine hydrochloride equivalent to 5 mg trifluoperazine. Available in bottles of 100 and 1000, and in unit dose packages of 100 (10 X10) tablets.

TRIFLUOPERAZINE 10 mg: Each deep blue, round, biconvex, film-coated tablet, engraved 10 on one side contains trifluoperazine hydrochloride equivalent to 10 mg trifluoperazine. Available in bottles of 100 and 1000 tablets.

TRIFLUOPERAZINE 20 mg: Each deep blue, round, biconvex, film-coated tablet, engraved 20 on one side contains trifluoperazine hydrochloride equivalent to 20 mg trifluoperazine. Available in bottles of 100.

7 Warnings and Precautions

See [3 Serious Warnings and Precautions Box](#).

General

Body Temperature Regulation: Disruption of the body's ability to reduce core body temperature has been attributed to antipsychotic agents. Hyperpyrexia has been reported with other antipsychotic drugs. Appropriate care is advised when prescribing TRIFLUOPERAZINE to patients who will be experiencing conditions which may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity or being subject to dehydration.

Long-Term Therapy: With prolonged administration at high dosages, the possibility of cumulative effects, with sudden onset of severe CNS or vasomotor symptoms, should be kept in mind. To lessen the likelihood of adverse reactions related to cumulative drug effect, patients with a history of long-term therapy with trifluoperazine tablets and/or other antipsychotics should be evaluated periodically to decide whether the maintenance dosage could be lowered or drug therapy discontinued.

Patients on long-term phenothiazine therapy require regular and careful surveillance with particular attention to tardive dyskinesia and possible eye changes, blood dyscrasias, liver dysfunction and myocardial conduction defects, particularly if other concurrently administered drugs have potential effects in these systems.

Although phenothiazines cause neither psychic nor physical dependence, sudden discontinuance in long-term psychiatric patients may cause temporary symptoms, e.g., nausea and vomiting, dizziness, tremulousness.

Carcinogenesis and Mutagenesis

Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin-dependent in vitro, a factor of potential importance if the prescription of neuroleptic drugs is contemplated in a patient with a previously detected breast cancer. An increase in mammary neoplasms has been found in rodents after chronic administration of neuroleptic drugs. The clinical significance of elevated serum prolactin levels is unknown for most patients. Neither clinical studies, nor epidemiological studies conducted to date, have shown an association between chronic administration of these drugs and mammary tumorigenesis; the available evidence is considered too limited to be conclusive at this time.

Phenothiazines have been found to be mutagenic with in vivo administration to rodents and in vitro administration to human cells and bacteria. No clinical relevance has been established.

Cardiovascular

Potential for Hypotension: Hypotension may very rarely occur. Patients receiving TRIFLUOPERAZINE should be observed for evidence of hypotension. Some individuals, especially the elderly or debilitated, have demonstrated transient hypotension for several hours following drug administration.

Phenothiazines can produce alpha-adrenergic blockade. Because hypotension has occurred, large doses should be avoided in patients with impaired cardiovascular systems. To further minimize the occurrence of hypotension after initial administration, keep patient lying down and observe for at least 0.5 hour. If hypotension occurs, place patient in head-low position with legs raised. If a vasoconstrictor is required, norepinephrine or phenylephrine is suitable. Other pressor agents, including epinephrine, should not be used as they may cause a paradoxical further lowering of blood pressure. See [5 Overdose](#).

TRIFLUOPERAZINE therapy may produce an increase in mental and physical activity. In certain instances, this effect may not be desirable. For example, some patients with angina pectoris have complained of increased pain while taking trifluoperazine tablets; therefore, if trifluoperazine is used in angina patients, such patients should be observed carefully and if an unfavorable response is noted, the drug should be withdrawn.

Prolongation of QT Interval: TRIFLUOPERAZINE is contraindicated in patients with a family history of QT prolongation; therefore, avoid concomitant use with QT prolonging drugs. Use with caution in patients with cardiovascular disease (see [2 Contraindications](#)).

Particular care should be exercised when administering TRIFLUOPERAZINE or its use avoided in patients who are suspected to be at an increased risk of experiencing Torsade de Pointes during treatment with a QT/QTc-prolonging drug (see [2 Contraindications](#)). Risk factors for Torsade de Pointes in the general population include, but are not limited to, the following:

- female
- age 65 years or older
- baseline prolongation of the QT/QTc interval
- presence of genetic variants affecting cardiac ion channels or regulatory proteins, especially congenital long QT syndromes
- family history of QT prolongation, or sudden cardiac death at <50 years
- cardiac disease (e.g., myocardial ischemia or infarction, congestive heart failure, left ventricular hypertrophy, cardiomyopathy, conduction system disease)
- history of arrhythmias (especially ventricular arrhythmias, atrial fibrillation, or recent conversion from atrial fibrillation)
- electrolyte disturbances (e.g., hypokalemia, hypomagnesemia, hypocalcemia)
- bradycardia
- acute neurological events (e.g., intracranial or subarachnoid haemorrhage, stroke, intracranial trauma)
- hepatic dysfunction, renal dysfunction, and/or phenotypic/genotypic poor metabolizers of

- drug metabolizing enzyme isoforms, if relevant to the elimination of the drug.
- diabetes mellitus
- nutritional deficit
- autonomic neuropathy

Physicians who prescribe drugs that prolong the QT/QTc interval should counsel their patients concerning the nature and implications of the ECG changes, underlying diseases and disorders that are considered to represent risk factors, demonstrated and predicted drug-drug interactions, symptoms suggestive of arrhythmia, risk management strategies, and other information relevant to the use of the drug.

Dependence, Tolerance, and/or Abuse Liability

Although phenothiazines cause neither psychic nor physical dependence, sudden discontinuance in long-term psychiatric patients may cause temporary symptoms, e.g., nausea and vomiting, dizziness, tremulousness.

Driving and Operating Machinery

TRIFLUOPERAZINE may impair mental and/or physical abilities, especially during the first few days of therapy.

While taking TRIFLUOPERAZINE, patients should be cautioned not to drive, operate dangerous machinery or engage in activities that require alertness or physical coordination if they are experiencing any of these effects.

Endocrine and Metabolism

Hyperprolactinemia: Hormonal effects of antipsychotic/neuroleptic drugs include hyperprolactinaemia, which may cause galactorrhoea, gynecomastia, oligomenorrhea or amenorrhoea, and erectile dysfunction. Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone mineral density in both female and male subjects.

Hyperglycemia: Diabetic ketoacidosis has occurred in patients with no reported history of hyperglycemia. Patients should have baseline and periodic monitoring of blood glucose and body weight.

Gastrointestinal

The antiemetic action of trifluoperazine tablets may mask signs and symptoms of toxicity or overdosage of other drugs or may obscure the diagnosis of conditions such as intestinal obstruction, brain tumor and Reye's syndrome.

Genitourinary

Rare cases of priapism have been reported with antipsychotics drug. This adverse reaction, as with other psychotropic drugs, did not appear to be dose-dependent and did not correlate with the duration of treatment.

Hematologic

Rare cases of blood dyscrasias (agranulocytosis, anemia, leukopenia, neutropenia, pancytopenia, thrombocytopenia) and jaundice of the cholestatic type have been reported in patients receiving high doses of trifluoperazine tablets. Therefore, the physician should bear in mind the possibility of such reactions and hematological monitoring is recommended.

Patients who have experienced blood dyscrasias or bone marrow suppression with a phenothiazine should not be re-exposed to any phenothiazine, including trifluoperazine tablets unless in the judgement of the healthcare professional the potential benefits of treatment outweigh the possible hazards.

Venous thromboembolism (VTE): Venous thromboembolism (VTE), including fatal pulmonary embolism, has been reported with antipsychotic drugs, including trifluoperazine tablets, in case reports and/or observational studies. When prescribing TRIFLUOPERAZINE all potential risk factors for VTE should be identified and preventative measures undertaken.

Hepatic/Biliary/Pancreatic

Jaundice of the cholestatic type of hepatitis or liver damage has been reported. Patients who have experienced jaundice with a phenothiazine should not be re-exposed to any phenothiazine, including trifluoperazine tablets, unless in the judgement of the healthcare professional the potential benefits of treatment outweigh the possible hazards. Hepatic and renal function should be checked.

Monitoring and Laboratory Tests

Phenothiazines may result in falsely positive or negative pregnancy test results due to interference based on immunological reactions between human chorionic gonadotropin (HCG) and anti-HCG.

Neurologic

Neuroleptic Malignant Syndrome (NMS): Patients treated with TRIFLUOPERAZINE can develop neuroleptic malignant syndrome: an idiosyncratic response characterized by hyperthermia, generalised muscle rigidity, autonomic instability (irregular pulse or blood pressure and diaphoresis), and altered consciousness. Patients with Parkinson's disease or dementia may be at increased risk. Hyperthermia is often an early sign of this syndrome.

Tardive Dyskinesia: As with all antipsychotic agents, tardive dyskinesia may appear in some patients on long-term therapy or after drug discontinuation. The syndrome is mainly characterized by rhythmical involuntary movements of the tongue, face, mouth or jaw. The manifestations may be permanent in some patients.

Extrapyramidal Symptoms: In common with all neuroleptics, extrapyramidal symptoms may occur. See [8.1 Adverse Reaction Overview, Extrapyramidal Symptoms](#).

Anticonvulsants: Since TRIFLUOPERAZINE may lower the convulsive threshold, it should be used with caution in patients with epilepsy, EEG abnormalities or subcortical brain damage. Dosage adjustment of anti-convulsant may be necessary.

Ophthalmologic

Phenothiazines have been reported to produce retinopathy, especially with long-term treatment at high dosage. Should ophthalmoscopic examination or visual field studies demonstrate retinal changes in patients on trifluoperazine tablets, the drug should be discontinued.

Angle-Closure Glaucoma: As with other antipsychotics, TRIFLUOPERAZINE can cause mydriasis, which may trigger an angle-closure attack in a patient with anatomically narrow ocular angles. Healthcare professionals should inform patients to seek immediate medical assistance if they experience eye pain, changes in vision or swelling or redness in or around the eye.

As with all drugs which exert an anticholinergic effect or cause mydriasis, TRIFLUOPERAZINE should be used with caution in patients with glaucoma.

Skin

Skin pigmentation have been reported in a few hospitalized mental patients taking substantial doses of some phenothiazine derivatives for prolonged periods. Present evidence suggests that these changes may be reversible.

7.1 Special Populations

7.1.1 Pregnancy

Safety for the use of trifluoperazine tablets during pregnancy has not been established.

When given in high doses during late pregnancy, phenothiazines have caused prolonged extrapyramidal disturbances in the child. There are also reports of prolonged jaundice and hyperreflexia or hyporeflexia in newborn infants whose mothers received phenothiazines.

Animal reproduction studies and follow-up studies in 819 women in Canada and Great Britain, who had taken trifluoperazine tablets during pregnancy, showed no causal relationship between the drug and congenital malformations. Nonetheless, it should not be administered to pregnant

women, particularly during the first trimester of pregnancy, unless, in the opinion of the physician, the expected benefits of the drug to the patient outweigh the potential risk to the fetus or child.

7.1.2 Breastfeeding

There is evidence that phenothiazines are excreted in the milk of nursing mothers.

Because of the potential for serious adverse reactions in nursing infants from trifluoperazine, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

7.1.3 Pediatrics

Pediatrics (<6 years of age): The safety and efficacy of trifluoperazine tablets in children under the age of 6 have not been studied; therefore, Health Canada has not authorized an indication for children under the age of 6 years. See [1.1 Pediatrics](#).

7.1.4 Geriatrics

Geriatrics (≥65 years of age): The safety and efficacy of trifluoperazine tablets in patients 65 years of age or older have not been studied. Caution should be exercised with the use of TRIFLUOPERAZINE in the elderly patient, recognizing the more frequent hepatic, renal, central nervous system, and cardiovascular dysfunctions, and more frequent use of concomitant medication in this population. See [4.1 Dosing Considerations, Geriatrics](#).

Use in Geriatric Patients with Dementia

Overall Mortality

Care should be exercised in treating elderly or debilitated patients as some appear prone to neurological adverse reactions.

Elderly patients with dementia treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo.

Analyses of thirteen placebo controlled trials with various atypical antipsychotics (modal duration of 10 weeks) in these patients showed a mean 1.6 fold increase in death rate in the drug-treated patients. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.

Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality.

The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear.

TRIFLUOPERAZINE is not indicated for the treatment of elderly patients with dementia.

8 Adverse Reactions

8.1 Adverse Reaction Overview

Adverse effects with different phenothiazines vary in type, frequency, and mechanism of occurrence, i.e., some are dose-related, while others involve individual patient sensitivity. Some adverse effects may be more likely to occur in patients with special medical problems, e.g., patients with mitral insufficiency or pheochromocytoma have experienced severe hypotension following recommended doses of certain phenothiazines.

At therapeutic dosage levels, adverse reactions are uncommon (infrequent), usually mild and transient; and unlikely to affect the course of treatment. Drowsiness, dizziness, skin reactions, dry mouth, stimulation, insomnia, fatigue, weakness, anorexia, amenorrhea, lactation and blurred vision may be seen occasionally. Extrapyramidal symptoms may occur but are rare at dosages of 6 mg or less. Tardive dyskinesia has been reported.

TRIFLUOPERAZINE may impair mental and/or physical abilities, especially during the first few days of therapy. Patients should be cautioned about activities requiring alertness, e.g., driving a car or operating machinery.

Neuroleptic Malignant Syndrome (NMS) has been reported in association with antipsychotic drugs. See [7 Warnings and Precautions, Neurologic, Neuroleptic Malignant Syndrome](#).

Extrapyramidal Symptoms

These symptoms are seen in a significant number of hospitalized mental patients receiving higher dosages of trifluoperazine tablets (10 mg to 40 mg or more daily). They may be characterized by motor restlessness, may be of the dystonic type, or may resemble parkinsonism.

Depending on the severity of symptoms, dosage should be reduced or discontinued. If therapy is reinstituted, it should be a lower dosage. Should these symptoms occur in children or pregnant patients, the drug should be stopped and not reinstated. Administration of an antiparkinsonism agent (except levodopa) can be considered for severe cases. Suitable supportive measures such as maintaining a clear airway and adequate hydration should be employed.

Motor Restlessness

Symptoms may include agitation or jitteriness and sometimes insomnia. These symptoms often disappear spontaneously. At times these symptoms may be similar to the original neurotic or psychotic symptoms. Dosage should not be increased until these side effects have subsided.

Dystonias

Symptoms may include spasm of the neck muscles, sometimes progressing to, torticollis; extensor

rigidity of back muscles; sometimes progressing to opisthotonos; carpopedal spasm, trismus, swallowing difficulty, oculogyric crises and protrusion of the tongue. The onset of the dystonias may be sudden. They may last several minutes, disappear and then recur. Prodromic symptoms are usually present. There is typically no loss of consciousness. They usually subside within a few hours, and almost always within 24 to 48 hours after the drug has been discontinued. In mild cases, reassurance is often sufficient. In more severe adult cases, the administration of an antiparkinsonism agent, except levodopa, usually improve symptoms. In children, reassurance will usually control symptoms.

Neuroleptic Malignant Syndrome

As with other neuroleptic drugs, a symptom complex sometimes referred to as neuroleptic malignant syndrome (NMS) has been reported. Cardinal features of NMS are hyperpyrexia, muscle rigidity, altered mental status (including catatonic signs), and evidence of autonomic instability (irregular pulse or blood pressure). Additional signs may include elevated CPK, myoglobinuria (rhabdomyolysis), and acute renal failure. NMS is potentially fatal and requires symptomatic treatment and immediate discontinuation of neuroleptic treatment.

Pseudoparkinsonism

Symptoms may include mask-like facies, drooling, tremor, pill-rolling motion, cogwheel rigidity and shuffling gait. Reassurance and sedation are important. In most cases these symptoms are reversible when an antiparkinsonism agent is administered concomitantly. Antiparkinsonism agents should be used only when required. (Note: Levodopa has not been found effective in pseudoparkinsonism). Occasionally it is necessary to lower the dosage or discontinue the drug temporarily.

Tardive Dyskinesia

This syndrome may occur in some patients on long-term therapy with phenothiazines, including trifluoperazine, or may appear after drug treatment has been discontinued. The risk appears to be greater in elderly patients, especially females, on high-dose therapy. The syndrome is characterized by rhythmical involuntary movements of the tongue and facial muscles (e.g., protrusion of the tongue, puffing of cheeks, puckering of mouth, chewing movements) and sometimes of the extremities. The symptoms may persist for many months or even years, and while they gradually disappear in some patients, they appear to be irreversible in others.

There is no known effective treatment for tardive dyskinesia; antiparkinsonism agents usually do not alleviate the symptoms. It is suggested that all antipsychotic agents be discontinued if these symptoms appear. If there is a reinstitution of treatment, or an increase in the dosage of the drug, or a switch to a different antipsychotic agent, the syndrome may be masked. It has been reported that fine vermicular movements of the tongue may be an early sign of the syndrome and if the medication is stopped at that time, the syndrome may not develop.

Other Adverse Reactions

Not all of the following adverse effects have been seen with every phenothiazine, however they have been reported with use of this drug class.

Blood and lymphatic system disorders: Blood dyscrasias including pancytopenia, agranulocytosis, thrombocytopenic purpura, leukopenia, eosinophilia, haemolytic anaemia, aplastic anaemia. See [Warnings and Precautions, Hematologic](#).

Cardiac disorders: Cardiac arrhythmias including atrioventricular block, paroxysmal tachycardia, ventricular fibrillation and cardiac arrest, ventricular arrhythmias, and Torsades de pointes.

Eye disorders: Blurred vision, miosis, mydriasis.

Gastrointestinal disorders: Mouth dryness, nausea, constipation, ileus.

General disorders and administration site conditions: Fatigue

Investigations: ECG changes, particularly nonspecific, usually reversible Q and T wave distortions, have been observed in some patients receiving phenothiazine tranquilizers. This relationship to myocardial damage has not been confirmed.

Other ECG changes can include non-specific transient Q and T wave abnormalities, QT Prolongation.

Musculoskeletal and connective tissue disorders: Muscular weakness.

Nervous system disorders: Drowsiness, dizziness, seizures (particularly in patients with EEG abnormalities), altered CSF proteins, cerebral edema, prolongation of the action of CNS depressants (opiates, alcohol, barbiturates), headache.

Psychiatric disorders: Reactivation of psychotic processes (catatonic-like states), increased aggressiveness, and toxic confusional states.

Respiratory thoracic and mediastinal disorders: Nasal congestion.

Renal and urinary disorders: Urinary retention.

Reproductive system and breast disorders: Impotence, priapism,

Vascular disorders: Hypotension.

9 Drug Interactions

9.1 Serious Drug Interactions

Serious Drug Interactions

- **Drugs that Prolong QT Interval:** Concomitant use of trifluoperazine tablets with drugs known to prolong the QT interval are contraindicated. See [2 Contraindications](#) and [9.2 Drug Interactions Overview, Drugs that Prolong QT Interval](#).
- **Selective Serotonin Reuptake Inhibitors:** TRIFLUOPERAZINE is contraindicated in combination with serotonin reuptake inhibitors, such as citalopram. See [2 Contraindications](#) and [9.2 Drug Interactions Overview, SSRI \(Selective Serotonin Reuptake Inhibitor\) Antidepressants](#).

9.2 Drug Interactions Overview

Drugs that Prolong QT Interval

Concomitant use of trifluoperazine tablets with drugs known to prolong the QT interval are contraindicated. See [2 Contraindications](#).

Drugs that have been associated with QT/QTc interval prolongation and/or torsade de pointes include, but are not limited to, the examples in the following list. Chemical/pharmacological classes are listed if some, although not necessarily all, class members have been implicated in QT/QTc prolongation and/or torsade de pointes:

- Class IA antiarrhythmics (e.g., quinidine, procainamide, disopyramide)
- Class III antiarrhythmics (e.g., amiodarone, sotalol, ibutilide)
- antipsychotics (e.g., chlorpromazine, pimozide, droperidol)
- antidepressants (e.g., fluoxetine, venlafaxine, tricyclic/tetracyclic antidepressants)
- opioids (e.g., methadone)
- macrolide antibiotics and analogues (e.g., erythromycin, clarithromycin)
- quinolone antibiotics (e.g., moxifloxacin)
- pentamidine
- antimalarials (e.g., quinine)
- azole antifungals (e.g., fluconazole, itraconazole, ketoconazole, voriconazole)
- domperidone
- tacrolimus
- 5-HT₃ antagonists (e.g., dolasetron, ondansetron)
- beta-2 adrenoceptor agonists (e.g., salmeterol, formoterol)

Particular care should be taken to avoid toxic plasma levels of lithium when this agent is administered together with TRIFLUOPERAZINE, since such toxic levels have also been associated with QT prolongation.

Do not administer in combination with drugs causing electrolyte alteration. Concomitant use with diuretics should be avoided, in particular those causing hypokalemia.

SSRI (Selective Serotonin Reuptake Inhibitor) Antidepressants

Combination with serotonin reuptake inhibitors, such as citalopram may result in an increased risk of QT interval prolongation.

9.3 Drug-Behaviour Interactions

If alcohol is used either simultaneously or successively with TRIFLUOPERAZINE, the possibility of an undesirable additive depressant effect should be considered.

9.4 Drug-Drug Interaction

The drugs listed in this table are based on either drug interaction case reports or studies, or potential interactions due to the expected magnitude and seriousness of the interaction (i.e., those identified as contraindicated).

Table 2 - Established or Potential Drug-Drug Interactions

Proper/Common name	Source of Evidence	Effect	Clinical comment
Anticholinergics (muscle relaxants)	T	Phenothiazines have mild anticholinergic activity which may be enhanced by other anticholinergic drugs. Anticholinergic drugs may decrease the antipsychotic effect of phenothiazines.	Dosage adjustment maybe necessary.

Proper/Common name	Source of Evidence	Effect	Clinical comment
Anticonvulsants	T	Phenothiazines may lower the convulsive threshold. Potentiation of anticonvulsant effects does not occur. However, it has been reported that phenothiazines may interfere with the metabolism of phenytoin and thus precipitate phenytoin toxicity.	Dosage adjustment of anticonvulsants may be necessary.
Antihypertensives	T	Antipsychotics, notably the phenothiazines, have blocked the action of antihypertensive agents.	Concomitant administration of antihypertensive agents should be undertaken with caution.
Atropine	T	Phenothiazines may potentiate the effect of atropine.	-
Gastro-intestinal agents that are not absorbed (magnesium, aluminium and calcium salts, oxides and hydroxides)	T	Reduced gastro-intestinal absorption of phenothiazine neuroleptics may occur.	Such gastro-intestinal agents should not be taken at the same time as phenothiazine neuroleptics (at least 2 hours apart, if possible).
Levodopa	T	TRIFLUOPERAZINE may, in a dose-related way, impair the antiparkinson effect of levodopa.	-

Proper/Common name	Source of Evidence	Effect	Clinical comment
Metrizamide	T	TRIFLUOPERAZINE should be discontinued at least 48 hours before myelography, should not be resumed for at least 24 hours post procedure, and should not be used for the control of nausea and vomiting occurring either prior to myelography or post procedure.	Drugs that lower the seizure threshold, including phenothiazine derivatives, should not be used with metrizamide.
Oral anticoagulants	T	Phenothiazines may diminish the effect of oral anticoagulants.	-
Organophosphate insecticides	T	Phenothiazines may potentiate the effect of organophosphate insecticides.	-
Propranolol	T	Concomitant administration of propranolol with phenothiazines results in increased plasma levels of both drugs.	-

Proper/Common name	Source of Evidence	Effect	Clinical comment
Sedatives, narcotics, anesthetics, tranquilizers, barbiturates, opiates, and other CNS depressants.	T	<p>If agents such as sedatives, narcotics, anesthetics, tranquilizers are used either simultaneously or successively with TRIFLUOPERAZINE, the possibility of an undesirable additive depressant effect should be considered.</p> <p>Phenothiazines may increase the effects of general anesthetics, opiates, barbiturates, alcohol and other CNS depressants.</p> <p>Other CNS depressants include morphine derivatives (analgesics, antitussives and substitution treatments), barbiturates, benzodiazepines, anxiolytics other than benzodiazepines, hypnotics, sedative anti-depressants, histamine H₁ receptor antagonists, central antihypertensive agents increased central depression. Changes in alertness can make it dangerous to drive or operate machinery.</p>	Dosage adjustment may be necessary.

T = Theoretical

9.5 Drug-Food Interactions

Interactions with food have not been established.

9.6 Drug-Herb Interactions

Interactions with herbal products have not been established.

9.7 Drug-Laboratory Test Interactions

Phenothiazines may result in falsely positive or negative pregnancy test results due to interference based on immunological reactions between human chorionic gonadotropin (HCG) and anti-HCG.

10 Clinical Pharmacology

10.1 Mechanism of Action

The mode of action of the phenothiazines has not yet been definitely established. Existing information suggests the following possibilities:

Antipsychotic/antianxiety effects:

Observations suggest that the primary action is to depress the physiologic accompaniments of the emotional factors of the personality which are believed to be basically evoked by the limbic system and its connections with the hypothalamus.

Experimental and clinical evidence indicates that the phenothiazines act on the subcortical areas of the CNS which influence the affective functions. Trifluoperazine is more specific than other phenothiazines in its activity. Its effects seem limited to parts of the basal ganglia, such as the amygdaloid nucleus.

The fact that trifluoperazine modifies behavior of opposite extremes toward more normal activity suggests that the drug is not working on behavior per se but on some factor or factors underlying behavior. Its rapidity of action, increased potency and effectiveness in chronic regressed patients in whom other agents were less effective are believed due to its specificity of action.

Antiemetic effect:

The phenothiazines (including TRIFLUOPERAZINE) inhibit indirect stimulation of the vomiting centre, but do not inhibit indirect stimulation of the centre by gastrointestinal stimulants. Because of this, it is believed that their site of action is the chemoreceptor trigger zone.

Onset of action occurs normally within 0.5 to 1 hour following tablet administration. Onset is slightly more rapid with the concentrate form because no disintegration time is involved. Onset usually occurs within 10 to 15 minutes when trifluoperazine is administered i.m., and within 5 to 15 minutes following i.v. administration. Peak activity occurs within 2 hours in animals. Clinical observations indicate that disappearance of, or marked reduction in psychomotor activity and hallucinations, occurs within hours after i.m. administration of trifluoperazine.

10.2 Pharmacodynamics

Information is not available.

10.3 Pharmacokinetics

Information is not available.

11 Storage Stability, and Disposal

Store at controlled room temperature 15°C-30°C in well-closed containers. Protect from light.

TRIFLUOPERAZINE should never be disposed of in household trash. Disposal via a pharmacy take back program is recommended.

Part 2: Scientific Information

13 Pharmaceutical Information


Drug Substance

Non-proprietary name of the drug substance(s): Trifluoperazine Hydrochloride BP

Chemical name: 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)-10H-phenothiazine

Molecular formula and molecular mass: $C_{21}H_{24}F_3N_3S$, 2HCl and 480.4 g/mol

Structural formula:



Physicochemical properties:

Melting Range:

~ 242 °C, with decomposition.

Description:

White to pale yellow, crystalline powder.

Pharmaceutical standard:

BP

14 Clinical Trials

The clinical trial data on which the indication was originally authorized is not available.

16 Non-Clinical Toxicology

Information is not available.

Patient Medication Information

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

PrTRIFLUOPERAZINE

trifluoperazine tablets

This patient medication information is written for the person who will be taking **TRIFLUOPERAZINE**. This may be you or a person you are caring for. Read this information carefully. Keep it as you may need to read it again.

This patient medication information is a summary. It will not tell you everything about this medication. If you have more questions about this medication or want more information about **TRIFLUOPERAZINE**, talk to a healthcare professional.

Serious warnings and precautions box

- TRIFLUOPERAZINE belongs to a group of medicines called antipsychotics. These medicines have been linked to a higher rate of death when used in elderly patients with dementia (loss of memory and other mental abilities).
- TRIFLUOPERAZINE is **not** to be used if you are elderly and have dementia.

What TRIFLUOPERAZINE is used for:

TRIFLUOPERAZINE is used in adults and children to:

- control symptoms of excessive anxiety, tension and agitation associated with certain mental health conditions.
- treat or prevent nausea and vomiting.
- manage the symptoms of psychotic disorders such as:
 - certain types of schizophrenia and psychosis; and
 - the manic episodes in bipolar disorder.

TRIFLUOPERAZINE is not indicated for children younger than 6 years of age.

How TRIFLUOPERAZINE works:

TRIFLUOPERAZINE is an antipsychotic medication which affects chemicals in the brain that allow communication between nerve cells (neurotransmitters). These chemicals are called dopamine and serotonin. Exactly how TRIFLUOPERAZINE works is unknown. However, it seems to readjust the balance of dopamine and serotonin.

The ingredients in TRIFLUOPERAZINE are:

Medicinal ingredient: Trifluoperazine hydrochloride

Non-medicinal ingredients: Carnauba wax, corn starch (1 mg, 2 mg), croscarmellose sodium (5 mg, 10 mg and 20 mg), hydroxypropyl methylcellulose, lactose monohydrate, indigotine AL lake 12-14% (Blue #2), magnesium stearate, microcrystalline cellulose, polyethylene glycol and titanium dioxide.

TRIFLUOPERAZINE comes in the following dosage form:

Tablets: 1 mg, 2 mg, 5 mg, 10 mg and 20 mg trifluoperazine (as trifluoperazine hydrochloride).

Do not use TRIFLUOPERAZINE if:

- you have an allergy to trifluoperazine, phenothiazines (a type of antipsychotic) or to any of the other ingredients in TRIFLUOPERAZINE.
- you are in a deep state of prolonged unconsciousness (coma) or have decreased alertness caused by certain medications or alcohol.
- you have liver damage.
- you have a blood cell disorder (e.g., low levels of red or white blood cells, or platelets).
- you have bone marrow depression (a condition where the bone marrow does not make enough blood cells and platelets).
- you have or have a family history of long QT syndrome (a heart rhythm condition that causes fast, chaotic heartbeats) or develop this syndrome during your treatment with TRIFLUOPERAZINE.
- you have or have had a condition that causes you to have an abnormal heart rhythm (e.g., Torsade de Pointes, atrial fibrillation, low heart rate).
- you take any medications that affect how your heart beats. For example:
 - medicines used to treat an abnormal heart rhythm.
 - antidepressant medications known as Selective Serotonin Reuptake Inhibitors (SSRIs) (e.g., citalopram).
 - any medications that can cause an electrolyte imbalance (e.g., diuretics, also known as “water pills”).

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take TRIFLUOPERAZINE. Talk about any health conditions or problems you may have, including if you:

- are currently taking any other medicines.
- are addicted to alcohol. You should not take TRIFLUOPERAZINE if you are under the effects of alcohol.

- exercise strenuously. TRIFLUOPERAZINE may interfere with your body's ability to adjust to heat. Avoid becoming overheated or dehydrated (for example with vigorous exercise or exposure to extreme heat) while taking TRIFLUOPERAZINE.
- have or have had breast cancer.
- are prone to low blood pressure.
- have chest pain (angina pectoris).
- have a condition that affects your heart and blood vessels.
- are at risk for Torsade de Pointes (a heart rhythm condition). Risk factors include, but are not-limited to:
 - being female.
 - being 65 years of age or older.
 - being genetically predisposed for heart rhythm conditions.
 - having a family history of sudden death in individuals less than 50 years of age.
 - having heart disease (e.g., heart attack, congestive heart failure, enlarged left ventricle of the heart, diseases affecting the electrical signals of your heart).
 - having an electrolyte imbalance (e.g., low levels of potassium, magnesium or calcium in the blood)
 - having a condition that affects the brain (e.g., brain bleed, stroke, head trauma).
 - having liver or kidney problems.
 - being known to poorly metabolize certain medicines.
 - having diabetes.
 - having poor nutrition.
 - having damage to the nerves that control automatic body functions (e.g., blood pressure, temperature control, bladder function, etc.).
- are at risk for developing blood clots. Risk factors include:
 - a family history of blood clots
 - being over the age of 65
 - smoking
 - being overweight
 - having a recent major surgery (such as hip or knee replacement)
 - not being able to move due to air travel or other reasons
 - taking oral birth control ("The Pill")
- have previously experienced jaundice with a phenothiazine (antipsychotic).
- have had long-term treatment with trifluoperazine tablets and/or other antipsychotic medications.
- have Parkinson's disease or dementia.
- have a medical condition known as pheochromocytoma (a tumour of the adrenal gland).
- have epilepsy, abnormal electrical activity in the brain or brain damage. TRIFLUOPERAZINE may make you more prone to seizures.
- suffer from an increased pressure within the eye(s) (glaucoma).

- have one of the following rare hereditary diseases:

- Galactose intolerance
- Lapp lactase deficiency
- Glucose-galactose malabsorption

Because lactose is a non-medicinal ingredient in TRIFLUOPERAZINE.

- are receiving or plan to receive:
 - anesthesia (medicines used to induce sleep and prevent pain during surgery).
 - computed tomography (CT) scans or radiography (X-ray imaging) with a chemical called metrizamide. TRIFLUOPERAZINE should not be taken with metrizamide. Your healthcare professional will tell you when to stop and resume your treatment with TRIFLUOPERAZINE for your examination.
- are pregnant, think you might be pregnant or are planning to become pregnant. TRIFLUOPERAZINE should not be used during pregnancy unless your healthcare professional considers that the benefits to you markedly outweigh the potential risks to the fetus.
- are breast-feeding or planning to breast-feed. TRIFLUOPERAZINE can pass into your breast milk and may harm a breast-fed baby. You and your healthcare professional will decide if you should take TRIFLUOPERAZINE or breast-feed. You should not do both.

Other warnings you should know about:

Driving and using machines: TRIFLUOPERAZINE may impair your mental and physical abilities. This may be more likely when you start your treatment. Before you drive or do tasks that require special attention, wait until you know how you respond to TRIFLUOPERAZINE. You should be cautious when driving a car or operating machinery.

Testing and check-ups: Your healthcare professional will monitor your health throughout your treatment. They may do this by performing certain tests before and periodically during your treatment. This will tell your healthcare professional how TRIFLUOPERAZINE is affecting you. These tests may monitor:

- the electrical activity of your heart (electrocardiogram; ECG);
- your blood sugar (glucose) level;
- your body weight;
- the profile of your blood (e.g., red blood cell, white blood cell, and platelet counts);
- your liver and kidney function; and
- your eyes.

Eye problems: TRIFLUOPERAZINE can cause eye problems such as mydriasis. Mydriasis is a condition where your pupils widen in an unusual way. This can cause a build-up of fluid and pressure in your eyes. Tell your healthcare professional right away if you experience visions changes, eye pain, redness in or around the eye.

Hyperprolactinemia (increased levels of prolactin): TRIFLUOPERAZINE can raise your levels of

a hormone called “prolactin”. This is measured with a blood test. Symptoms may include:

- In men:
 - swelling in the breast;
 - difficulty in getting or maintaining an erection or other sexual dysfunction.
- In women:
 - discomfort in the breasts;
 - leaking of milk from the breasts (even if not pregnant);
 - missing your menstrual period or other problems with your cycle.

If you have high levels of prolactin and a condition called hypogonadism, you may be at an increased risk of breaking a bone due to osteoporosis. This occurs in both men and women.

Pregnancy: You should not take TRIFLUOPERAZINE while you are pregnant or if you are planning on becoming pregnant unless you have talked to your healthcare professional about it. If you took TRIFLUOPERAZINE at any time while you were pregnant or if you took it before you became pregnant, the following symptoms may happen in your newborn baby:

- shaking;
- stiffness in their muscles and/or weakness;
- sleepiness;
- agitation;
- breathing problems; or
- difficulty feeding.

Get medical help right away if your newborn has any of these symptoms.

Taking TRIFLUOPERAZINE may also affect your pregnancy tests by producing false-positive or false-negative pregnancy results.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

Serious drug interactions:

Do not take TRIFLUOPERAZINE with:

- medicines that can affect how your heart beats. These include, but are not limited to:
 - medicines used to treat an abnormal heart rhythm (e.g., quinidine, procainamide, disopyramide, amiodarone, sotalol, ibutilide).
 - other antipsychotic medications (e.g., droperidol, chlorpromazine, pimozide).
 - medicines used to treat depression (e.g., fluoxetine, venlafaxine, tricyclic/tetracyclic antidepressants, selective serotonin reuptake inhibitors [SSRIs] such as citalopram).
 - opioids, medicines used to relieve pain (e.g., methadone, codeine).
 - medicines used to treat bacterial infections (e.g., erythromycin, clarithromycin,

moxifloxacin).

- pentamidine, used to treat a serious type of pneumonia (i.e., *Pneumocystis carinii* pneumonia).
- medicines used to treat malaria (e.g., quinine).
- medicines used to treat fungal infections (e.g., ketoconazole, fluconazole, itraconazole, voriconazole).
- domperidone, used to speed up the movements of the stomach and bowel.
- tacrolimus, used to prevent organ transplant rejection.
- other medicines used to treat nausea and vomiting (e.g., ondansetron).
- medicines used to treat breathing problems like asthma and lung disease (e.g., salmeterol, formoterol).
- lithium, used to treat mood disorders.
- medicines that can cause an electrolyte imbalance (e.g., diuretics, also known as “water pills”).

The following may also interact with TRIFLUOPERAZINE:

- alcohol. TRIFLUOPERAZINE can increase the effects of alcohol. You should avoid consuming alcohol while taking TRIFLUOPERAZINE.
- medicines used to control seizures (e.g., phenytoin).
- barbiturates, medicines used to relax the body and help with sleeping.
- medicines used to treat high blood pressure and certain heart conditions (e.g., propranolol).
- atropine, used to treat eye problems, a low heart rate, insecticide or mushroom poisoning, or reduce saliva and fluid in the respiratory tract during surgery.
- medicines used to treat gastrointestinal problems, such as magnesium, aluminum and calcium salts, oxides and hydroxides.
- phosphorus insecticides used for farming, treating animals (e.g., flea and tick control), and treating pests around the house or garden. TRIFLUOPERAZINE can increase the toxicity from these types of insecticides, so caution must be taken when using these products.
- sedatives and tranquilizers, medicines used to treat anxiety and/or insomnia.
- metrizamide, a radiocontrast agent used to improve the contrast of internal body structures using different imaging techniques such as computed tomography (CT) scans or radiography (X-ray imaging).
- anaesthetics, medicines used during surgery.
- levodopa, used to treat Parkinson’s disease.
- oral anticoagulants, medicines used to prevent and treat blood clots (e.g., warfarin).
- antacids, used to treat indigestion.
- muscle relaxants, medicines used to treat muscle spasms and back pain.
- antihistamines, medicines used to treat allergies and may cause drowsiness (e.g., diphenhydramine).
- medicines that may make you sleepy or drowsy (e.g., cough-and-cold medicines, sleeping pills). You should not take TRIFLUOPERAZINE if you have drowsiness caused by other medicines.

How to take TRIFLUOPERAZINE:

- Take TRIFLUOPERAZINE exactly as your healthcare professional has told you.
- Your healthcare professional will decide on the best dose for you depending on:
 - the severity of your symptoms; and
 - how you respond to your treatment.
- During the first few days of your treatment, your healthcare professional may gradually increase your dose. This is to allow your body to adjust and minimize side effects.
- Do not take TRIFLUOPERAZINE more often or increase your dose without consulting your healthcare professional. Taking more than you should will not improve your condition any faster. Instead, you will increase your risk of serious side effects.
- Do not stop taking this medicine suddenly without your healthcare professional's approval.

Usual dose:

Adults:

- **For mild to moderate symptoms:** The usual dose is 1 or 2 mg twice daily. If necessary, your dose may be increased to 6 mg daily. However, above this amount, side effects are more likely to occur in some patients.
- **For moderate to severe symptoms:** The usual starting dose is 5 mg, taken 2 or 3 times daily. Your dose will be increased gradually. The usual maintenance dose is 15 to 20 mg per day. However, some patients may require more.

Children:

- **For behavioural disorders:** The usual dose is 1 mg once or twice daily, depending on the child's bodyweight.
- **For psychosis:** The usual starting dose is 1 mg once or twice daily, depending on the child's bodyweight. The dose may be gradually increased until symptoms are controlled or until side effects become troublesome. The lowest effective dosage will be given. In most cases, it is not necessary to exceed 15 mg of TRIFLUOPERAZINE daily.

Overdose:

Symptoms of overdose with TRIFLUOPERAZINE include:

- muscle twitching
- drowsiness weakness
- shaking (tremor)
- irregular heartbeat
- low blood pressure
- agitation
- confusion
- dizziness
- increased salivation

- trouble swallowing
- loss of balance or coordination
- fainting
- repetitive and involuntary muscle contractions
- neck problems (torticollis)
- unusually weak breathing

If you think you, or a person you are caring for, have taken too much TRIFLUOPERAZINE, contact a healthcare professional, hospital emergency department, regional poison control centre or Health Canada's toll-free number, 1-844 POISON-X (1-844-764-7669) immediately, even if there are no signs or symptoms.

Missed dose:

If you miss a dose, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and take your next dose as scheduled. Never take two doses at once to make up for a missed dose.

Possible side effects from using TRIFLUOPERAZINE:

These are not all the possible side effects you may have when taking TRIFLUOPERAZINE. If you experience any side effects not listed here, tell your healthcare professional.

Side effects with TRIFLUOPERAZINE may include:

- feeling tired or weak
- feeling dizzy
- dry mouth
- lack of energy
- loss of appetite
- feeling agitated or jittery
- nausea
- constipation
- headache
- stuffy nose
- changes in bodyweight
- skin rashes, itching and redness
- skin colouring (pigmentation)
- trouble falling and/or staying asleep

Serious side effects and what to do about them

Frequency/Side Effect/Symptom	Talk to your professional		Stop taking this drug and get immediate medical help
	Only if severe	In all cases	
Uncommon			
Extrapyramidal reactions: muscle stiffness, body spasms, upward eye rolling, exaggeration of reflexes, drooling, difficulty moving how and when you want, masklike face (appears to lack emotion), tremors, drooling, or dragging feet as you walk, difficulty swallowing, a feeling of restlessness, or inability to remain motionless.			√
Dystonia: twisting movements that you cannot control and can affect posture or the face including eyes, mouth, tongue or jaw, tightness of the throat, difficulty swallowing or breathing which may lead to choking.			√
Neuroleptic malignant syndrome (NMS): pronounced muscle stiffness or inflexibility with high fever, rapid or irregular heartbeat, sweating, state of confusion, or reduced consciousness.			√
Tardive dyskinesia (TD): uncontrollable, unusual, or abnormal movements, muscle twitches of the body, face, mouth, eyes or tongue, or stretching the neck and body.		√	
Unknown			
Blood disorders (low blood platelet, low white blood cell, and/or low red blood cell counts): frequent infection with fever, chills, sore throat, fatigue, aches, pains, flu-like symptoms, paleness of the skin, rapid heart rate, shortness of breath, bruising easily, or heavy bleeding.			√
Heart problems: abnormally fast heartbeat, irregular heartbeat, chest pain, or changes in the rhythm of your heart.			√
Hyperprolactinemia (increased levels of prolactin): In men: swelling in the breast, difficulty in getting or maintaining an erection, or other sexual dysfunction. In women: discomfort in the breasts, leaking of milk from the breasts (even if not pregnant), or missing your menstrual period or other problems with your cycle.		√	

Frequency/Side Effect/Symptom	Talk to your professional		Stop taking this drug and get immediate medical help
	Only if severe	In all cases	
Breast cancer: new lump or mass in the breast or armpit, changes in the size, shape, texture or appearance of a breast, a nipple that looks flattened or turns inward.		√	
Eye problems: vision changes, blurred vision, sensitivity to light, pin point pupils, or other eye changes or disorder.			√
Paralytic ileus (muscles that move food through the intestines are paralyzed): new or worsening constipation, nausea, vomiting, dehydration, gas, or abdominal pain.		√	
Hyperglycemia (high blood sugar): increased thirst, frequent urination, dry skin, headache, blurred vision and fatigue.	√		
Overheating/dehydration (dry mouth, excessive thirst): thirst, headache, loss of appetite, feel tired and weak, lack of sweating, decreased blood pressure and urine, dark yellow urine.	√		
Liver problems (including hepatitis, cholestatic jaundice): upper right abdominal pain, pain in the back, nausea, vomiting, yellowing of the skin and white of eyes, dark urine, light coloured stool, or itching all over your body.			√
Allergic reaction: rash, hives, swelling of the face, lips, tongue or throat, difficulty swallowing or breathing, fever, asthma, wheezing, drop in blood pressure, feeling sick to your stomach, itchiness, or vomiting.			√
Seizures (fits): loss of consciousness with uncontrollable shaking.			√
Cerebral edema (swelling in the brain): severe headache, slow heart rate, irritability, weakness, difficulty talking, drowsiness, fainting, passing out, or vomiting.			√
Behavioural changes (including worsening of psychotic symptoms): abnormal thoughts, hallucinations, delusions, changes in sleep patterns, confusion, anxiety, anger, speech that doesn't make sense, problems concentrating, disorientation, or agitation.			√
Urinary retention (inability to pass urine or to empty the bladder): pain.		√	

Frequency/Side Effect/Symptom	Talk to your professional		Stop taking this drug and get immediate medical help
	Only if severe	In all cases	
Priapism (persistent and painful erection of the penis lasting longer than 4 hours).			√
Hypotension (low blood pressure): dizziness, fainting, light-headedness, blurred vision, nausea, vomiting, or fatigue (may occur when you go from lying or sitting to standing up).		√	
Blood clots: swelling, pain, redness in an arm or leg that can be warm to touch. You may develop sudden chest pain, difficulty breathing and heart palpitations.		√	

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Reporting side effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (canada.ca/drug-device-reporting) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your healthcare professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

- Store TRIFLUOPERAZINE at room temperature (15°C - 30°C) in well closed containers. Protect from light.
- Do not use after the expiry date shown on the packaging.
- Keep out of reach and sight of children.

If you want more information about TRIFLUOPERAZINE:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes the Patient Medication Information by visiting the Health Canada Drug Product Database

website ([Drug Product Database: Access the database](#)); the manufacturer's website (<https://www.aapharma.ca/en/>); or by calling 1-877-998-9097.

This leaflet was prepared by AA Pharma Inc. 1165 Creditstone Road Unit #1, Vaughan, Ontario, L4K 4N7.

Date of Authorization: April 16, 2025